Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ritlecitinib DDI with Tolbutamide in Healthy Participants
NCT05097716Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2021
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ritlecitinib tosilate in alopecia areata, sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration at 36 hours and Area Under the Plasma Concentration Time Profile to Infinite Time at 36 hours. Started Nov 2021; status: completed.
02
Drugs
ritlecitinib tosilate
03
Conditions
alopecia areata
Beyond the preview
Go deeper on NCT05097716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05097716.